Факторы роста, их рецепторы и нижележащие сигнальные белки: от эксперимента к клинике

ЕС Герштейн, НЕ Кушлинский - Успехи молекулярной онкологии, 2014 - cyberleninka.ru
В обзоре представлены основополагающие данные современной литературы и
результаты собственных многолетних исследований роли ауто/паракринных факторов …

Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab

M Yamazaki, Y Yamashita, N Kubo… - Oncology …, 2012 - spandidos-publications.com
The ERBB proteins are cell membrane tyrosine kinase receptors. Among these receptors,
ERBB1 (EGFR or HER1) and ERBB2 (HER2/Neu) have been reported to be the most …

Molecular imaging application of radioiodinated anti-EGFR human Fab to EGFR-overexpressing tumor xenografts

N Xu, G Cai, W Ye, X Wang, Y Li, P Zhao… - Anticancer …, 2009 - ar.iiarjournals.org
Background: Suitable diagnostics could identify patients who might benefit from targeted
therapies. Molecular imaging is a promising method estimating the expression of specific …

Validating pharmacological disruption of protein–protein interactions by acceptor photobleaching FRET imaging

J Roszik, G Tóth, J Szöllősi, G Vereb - Target Identification and Validation …, 2013 - Springer
Proteins are the major targets of drug discovery and many of the new drugs are designed to
exert their effect by disrupting protein-protein interactions. Validation of the inhibition of …

Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell …

S Sapski, N Beha, RE Kontermann, D Müller - Cancer Immunology …, 2020 - Springer
Target expression heterogeneity and the presence of an immunosuppressive
microenvironment can hamper severely the efficiency of immunotherapeutic approaches …

Pertuzumab increases 17-AAG-induced degradation of ErbB2, and this effect is further increased by combining pertuzumab with trastuzumab

JB Hughes, MS Rødland, M Hasmann, IH Madshus… - Pharmaceuticals, 2012 - mdpi.com
ErbB2 is an important oncogenic protein involved in carcinogenesis of, among others,
breast, gastric, and ovarian carcinoma. Over-expression of ErbB2 is found in almost 20% of …

The in vitro influences of epidermal growth factor and heregulin-β1 on the efficacy of trastuzumab used in Her-2 positive breast adenocarcinoma

T Hurrell, K Outhoff - Cancer cell international, 2013 - Springer
Background Human epidermal growth factor receptor-2 (Her-2) is over expressed in
approximately 25-30% of all primary breast tumors resulting in a distinctive breast cancer …

Development of an affinity-matured humanized anti-epidermal growth factor receptor antibody for cancer immunotherapy

T Nakanishi, T Maru, K Tahara… - … , Design & Selection, 2013 - academic.oup.com
We showed previously that humanization of 528, a murine anti-epidermal growth factor
receptor (EGFR) antibody, causes reduced affinity for its target. Here, to improve the affinity …

Resistance to cetuximab in EGFR-overexpressing esophageal squamous cell carcinoma xenografts due to FGFR2 amplification and overexpression

Y Zhang, T Pan, X Zhong, C Cheng - Journal of pharmacological …, 2014 - jstage.jst.go.jp
Esophageal carcinoma is one of the most virulent malignant diseases and a major cause of
cancer-related deaths worldwide. Despite improvements in surgical techniques and …

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted Therapy

C De Giovanni, L Landuzzi, A Palladini, G Nicoletti… - Cells, 2021 - mdpi.com
Rhabdomyosarcomas (RMS) are tumors of the skeletal muscle lineage. Two main features
allow for distinction between subtypes: morphology and presence/absence of a …